Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Liquid Biopsy In Oncology: An Increasingly Crowded Landscape

Executive Summary

Liquid biopsies – carrying out diagnostic tests on liquid samples such as blood or urine rather than on tissue biopsy material – look set to revolutionize the management of cancer patients. This area has recently captured the interest of a growing number of diagnostic players, both big and small, and spawned the development of different approaches to liquid biopsy. This article marks out who's who in this increasingly busy landscape and the key technologies that are showing promise, and looks at the obstacles that companies are facing.

Advertisement

Related Content

Angle Reels In Positive Clinical Results In Ovarian Cancer Study
Positive Data Backs Inivata's T790 Test For Use in Non-Biopsy Lung Cancer Patients
Can New Wave Of Tests Finally Nail Early Diagnosis Of Lung Cancer?
Menarini Bags J&J's Cellsearch To Strengthen Liquid Biopsy Offering
Device/Diagnostics Quarterly Deal Statistics, Q3 2016
Earnings Winners & Losers: QGEN, WMGI, ALR, SN, and LIVN
Inivata Launches Major US Study To Back Liquid Biopsy Tech In Lung Cancer
ASCO Round-Up: Chronix Delta Dots, HTG EdgeSeq, and Guardant360 Liquid Biopsy
Angle Strikes Out Into New Cancer Dx Markets
Chronix’s new liquid biopsy approach show promise as early predictor of cancer therapies

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

MT103794

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel